Thursday, November 14, 2024, Eli Lilly & Co of the company’s Digital Health Innovation Center facility. Logo.
Ore | Bloomberg | Getty Images
Yililai It said Thursday it expects to release data on its next generation of weight loss pills from later trials review Later this year, several months earlier than expected.
The company expects to conduct results of a study of obesity and knee osteoarthritis patients in 2025. Fourth quarter income Slideshow on its website. Eli Lilly has previously said that the third phase of the study is expected to be completed in February 2026.
It is at least nine close observations on vistrutide’s clinical trials that have different effects than obesity and diabetes treatments on the market and seem to be more effective in weight loss.
vistrutide is a key part of Eli Lilly’s medicine pipeline that can help companies maintain dominance in the blockbuster weight loss and diabetes treatment spaces and gain an edge over key competitors Novo nordisk. Called the “Triple G” drug, it mimics the effects of three starvation-regulated hormones: GLP-1, GIP and glucagon. This seems to have a greater impact on a person’s appetite and satisfaction with food.
Meanwhile, Tirzepatide – the weight loss lens of Eli Lilly and the active ingredient of the diabetes drug Mounjaro – mimics two hunger regulatory hormones, GLP-1 and GIP. Novo Nordisk’s weight loss medication only simulates GLP-1.
The treatment also appears to cause greater weight loss than Tirzepatide, while Tirzepatide demand surges in the United States
vistrutide helps patients lose an average of 24.2% of their weight (or 58 pounds) after 48 weeks Trial Obese or overweight adults. Those who took the placebo lost 2.1% of their weight after the same period.
Higher doses of Tirzepatide help obese patients lose 22.5% WeigerAverage loss of HT in late-stage studies.
– CNBC’s Angelica Peebles contributed to this report.
